Latest Articles and Analysis

CANN reflects on 2021 advocacy spanning 340B drug pricing, HIV, hepatitis C, and substance use disorder policy.

FDA reclassifies HCV testing to reduce regulatory burden and enable new test makers to enter market.

Q4 2021 Watch covering HCV drug formulary updates, ADAP and Medicaid changes, and pandemic impact on care.

Payers restrict HCV treatment through utilization management; patient assistance programs fill the critical gap.

Global Fund report shows COVID-19 reduced HIV/HCV program efficacy while South Africa tripled ART coverage.

31,000 Veterans with HIV face unique barriers including comorbidities and HCV rates 3x the general population.

Study explores social-spatial networks and HIV/HCV diagnosis rates among homeless and injection drug users.

Nobel laureate's HCV vaccine development targeting 2029 offers hope alongside access equity challenges.

WHO 2030 HCV elimination goal at risk; only 5 of 110 countries on track as COVID-19 disrupts progress.

Q3 2021 quarterly review of HCV drug access across ADAPs and Medicaid with harm reduction program updates.

CANN roundtable discusses pandemic's impacts on HIV, HCV, STI, and SUD programs and funding weaknesses.

Study of 109,283 patients links HIV status and viral hepatitis coinfection to significantly increased liver cancer rates.

Restrictive Medicaid policies limit HCV treatment access through fibrosis restrictions and sobriety requirements.

UNAIDS report highlights HIV-HCV coinfection rates among people who inject drugs globally and in the US.

Supreme Court allows states to ration hepatitis C care in prisons, setting dangerous precedent for incarcerated people.

Reviews Biden's first 100 days on healthcare: infrastructure, subsidies, harm reduction, and health equity.

Quarterly update on HCV treatment coverage across ADAPs, Medicaid, Veterans programs, and patient assistance options.

Housing instability increases HIV/HCV acquisition by 55-65%; housing investments outpace health interventions.

COVID-19 vaccination priority for people with HIV and chronic liver disease amid immunological risks.

Assesses pandemic's ongoing impact on HIV, HCV, and SUD surveillance and care with vaccine rollout.